诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

盘前交易 07-22 05:04:07 EDT

131.54

+1.55

+1.19%

盘前132.48

+0.94+0.71%

05:02 EDT

最高133.50	最低131.30	成交量431.95万
今开132.61	昨收129.99	日振幅1.69%
总市值5,833亿	流通市值4,168亿	总股本44.35亿
成交额5.71亿	换手率0.14%	流通股本31.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":131.54,"timestamp":1721419200000,"preClose":129.99,"halted":0,"volume":4319543,"hourTrading":{"tag":"盘前","latestPrice":132.48,"preClose":131.54,"latestTime":"05:02 EDT","volume":1466,"amount":193812.2368,"timestamp":1721638926737},"delay":0,"floatShares":3168455429,"shares":4434702140,"eps":2.879408,"marketStatus":"盘前交易","marketStatusCode":1,"change":1.55,"latestTime":"07-22 05:04:07 EDT","open":132.61,"high":133.5,"low":131.3,"amount":570679231.1479499,"amplitude":0.016924,"askPrice":132.64,"askSize":50,"bidPrice":132.58,"bidSize":200,"shortable":3,"etf":0,"ttmEps":2.879408,"exchange":"NYSE","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721655000000},"adr":1,"listingDate":363499200000,"adjPreClose":131.54,"adrRate":1,"dividendRate":0.010517,"preHourTrading":{"tag":"盘前","latestPrice":132.48,"preClose":131.54,"latestTime":"05:02 EDT","volume":1466,"amount":193812.2368,"timestamp":1721638926737},"postHourTrading":{"tag":"盘后","latestPrice":131.54,"preClose":131.54,"latestTime":"19:57 EDT","volume":573897,"amount":75492198.5602,"timestamp":1721433450508},"volumeRatio":0.9000968747708626,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1723780800000,"strike":"135.0","timestamp":1721406860718,"price":4.449999809265137,"volume":1150,"amount":511750,"type":"+"}]},"impliedVol":0.4061,"impliedVolPercentile":0.936},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2453786850","title":"最高减重20%！礼来“替尔泊肽”在华获批，效果强过司美格鲁肽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2453786850","media":"格隆汇","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453786850?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:20","pubTimestamp":1721614814,"startTime":"0","endTime":"0","summary":"竞争白热化？","market":"us","thumbnail":"https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1b662-9eab396d-85aa-4a35-807e-33d8ee710c4d.jpg?guru_height=908&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/869192","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK4534","LU1551013342.USD","LU1623119135.USD","LU2328871848.SGD","LU0122379950.USD","NVO","LU0256863811.USD","300199","603087","IE00BJT1NW94.SGD","BK4532","LU0096364046.USD","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0471298694.HKD","BK0183","LU0097036916.USD","LU0385154629.USD","000963","BK0187","BK0239","LU0061475181.USD","IE0002141913.USD","LU0109391861.USD","LU1804176565.USD","LI","BK4533","BK4516","LU0708995401.HKD","LU1280957306.USD","BK0188","LU0943347566.SGD","IE00BJLML261.HKD","IE00B1BXHZ80.USD","LU1061106388.HKD","BK0077","GB00BDT5M118.USD","IE0009355771.USD","LU0820561909.HKD","LU0114720955.EUR","BK0175","BK4007","LU1093756168.USD","LU0079474960.USD","LU1035775433.USD","LU0882574055.USD","LU0058720904.USD","LU0094547139.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2452062894","title":"减肥药赛道“搅局者”来了，两大巨头“硬碰硬”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452062894","media":"中国基金报","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452062894?lang=zh_cn&edition=full","pubTime":"2024-07-20 00:16","pubTimestamp":1721405811,"startTime":"0","endTime":"0","summary":"国内减重赛道迎来重磅级“选手”。7月19日，记者从国家药品监督管理局获悉，礼来的替尔泊肽注射液长期体重管理适应证获得批准，这是目前首个且是唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。一直以来，礼来与诺和诺德并称“GLP-1双雄”，后者拥有“减肥神药”司美格鲁肽，已在国内获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407203135777061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407203135777061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LLY","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","BK4585","BK4588","LU1093756168.USD","BK4007"],"gpt_icon":1},{"id":"2452742784","title":"司美格鲁肽的竞争对手来了 礼来替尔泊肽注射液体重管理适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452742784","media":"每日经济新闻","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452742784?lang=zh_cn&edition=full","pubTime":"2024-07-19 22:16","pubTimestamp":1721398617,"startTime":"0","endTime":"0","summary":"7月19日，礼来宣布，穆峰达（替尔泊肽注射液）长期体重管理适应症获得国家药品监督管理局（NMPA）批准。据介绍，穆峰达是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽（GIP）/胰高糖素样肽-1（GLP-1）受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135753480.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135753480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456855351.SGD","IE0002141913.USD","IE00B1BXHZ80.USD","LU0114720955.EUR","LU1804176565.USD","LU0079474960.USD","LU0417517546.SGD","LU0943347566.SGD","BK4534","LU1064131342.USD","LU0238689110.USD","BK4007","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4585","LU0471298694.HKD","NVO","LU0256863902.USD","LU0094547139.USD","LU1023059063.AUD","LU0109391861.USD","LU1267930730.SGD","LU0708995401.HKD","BK4588","LU0320765059.SGD","LU0640476718.USD","BK4581","BK4533","LU0058720904.USD","LU1035775433.USD","LU0061475181.USD","IE00BJLML261.HKD","LU1061106388.HKD","LLY","LU1551013342.USD","LU1551013425.SGD","LU0256863811.USD","LU0122379950.USD","IE00BK4W5M84.HKD","LU0198837287.USD","LU0471298777.SGD","IE00B2B36J28.USD","IE0004445239.USD","GB00BDT5M118.USD","LU0289739699.SGD","IE00BK4W5L77.USD","LU1280957306.USD","LU0882574055.USD","IE00BJT1NW94.SGD","LU0672654240.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2452420474","title":"BUZZ-减肥药在中国获批，礼来公司业绩上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2452420474","media":"Reuters","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452420474?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:29","pubTimestamp":1721392190,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    7月19日 - ** 礼来  股价盘前上涨2.4%至866.75美元 ** 公司称 (link) 其减肥药替西帕肽已获得中国监管机构的批准 ** 蒂塞帕肽是这家美国制药商的糖尿病药物Mounjaro（也在中国获批）和减肥药物Zepbound的活性成分** 礼来公司和丹麦制药商诺和诺德  在增加减肥药产量的竞争中遥遥领先，预计到2030年代初，减肥药市场将达到约1500亿美元的规模 (link)。** 截至上次收盘，该股今年累计上涨45.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1069344957.HKD","LU1804176565.USD","LU0882574055.USD","LU0943347566.SGD","IE0009355771.USD","LU0061475181.USD","LU0096364046.USD","BK4585","LU0097036916.USD","LU0466842654.USD","LU0640476718.USD","LLY","LU0823416689.USD","LU0882574139.USD","LU1551013342.USD","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU1035775433.USD","BK4516","LU0079474960.USD","LU0122379950.USD","LU0820561909.HKD","LU0385154629.USD","LU1061106388.HKD","LU0114720955.EUR","BK4533","LU0109391861.USD","IE0004445239.USD","IE00B1BXHZ80.USD","NVO","LU0094547139.USD","LU0820561818.USD","IE00BJLML261.HKD","BK4007","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0058720904.USD","LU0708995401.HKD","LU1551013425.SGD","LU0198837287.USD","LU1712237335.SGD","LU0256863811.USD","IE00BJT1NW94.SGD","LU1064131342.USD","GB00BDT5M118.USD","LU1623119135.USD","LU1280957306.USD","BK4534","IE00B4R5TH58.HKD","LU0689472784.USD"],"gpt_icon":1},{"id":"2452478682","title":"礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2452478682","media":"老虎证券","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452478682?lang=zh_cn&edition=full","pubTime":"2024-07-19 20:16","pubTimestamp":1721391360,"startTime":"0","endTime":"0","summary":"【礼来(LLY.US)减肥药在中国获批 将和诺和诺德(NVO.US)直接竞争】智通财经APP获悉，7月19日，礼来(LLY.US)穆峰达®(替尔泊肽注射液)长期体重管理适应症获得中国国家药品监督管理局(NMPA)批准。穆峰达®是首个且目前唯一获批的葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)受体激动剂，也是礼来肥胖治疗领域在中国获批的首个创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407192018579f6b9b35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0094547139.USD","LU0058720904.USD","GB00BDT5M118.USD","LU0882574055.USD","LU0122379950.USD","LU0320765059.SGD","BK4534","IE00B1BXHZ80.USD","BK4532","LU0471298694.HKD","LU1804176565.USD","LU0238689110.USD","LU1035775433.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","IE00BK4W5L77.USD","LU1093756325.SGD","IE00BK4W5M84.HKD","IE0004445239.USD","LU0109391861.USD","IE0002141913.USD","LU1280957306.USD","LU0154236417.USD","LU1023059063.AUD","BK4588","LU0417517546.SGD","LU0256863811.USD","LU0289739699.SGD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU1551013425.SGD","BK4533","LU1057294990.SGD","LU1061106388.HKD","IE00BJLML261.HKD","LU0061475181.USD","NVO","LU0114720955.EUR","LU0256863902.USD","LU0672654240.SGD","BK4516","LU0079474960.USD","LU0096364046.USD","BK4581","LU1093756168.USD","LU0097036916.USD","LLY","LU0708995401.HKD","BK4007"],"gpt_icon":1},{"id":"2452080424","title":"礼来替尔泊肽获批减重新适应症，GLP-1赛道掀王者之争孰胜孰负？","url":"https://stock-news.laohu8.com/highlight/detail?id=2452080424","media":"21世纪经济报道","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452080424?lang=zh_cn&edition=full","pubTime":"2024-07-19 19:25","pubTimestamp":1721388307,"startTime":"0","endTime":"0","summary":"7月19日，国家药品监督管理局（NMPA）官网显示，礼来的葡萄糖依赖性促胰岛素多肽（GIP）和胰高血糖素样肽-1（GLP-1）受体双重激动剂Mounjaro（Tirzepatide，替尔泊肽）新适应症获批上市，用于在低热量饮食和增加运动基础上改善成人肥胖或伴有至少一种体重相关合并症的超重患者长期体重管理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407193135667664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407193135667664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0708995401.HKD","IE00BJT1NW94.SGD","LU0097036916.USD","LU0820561818.USD","LU1023059063.AUD","NVO","GB00BDT5M118.USD","LLY","LU1069344957.HKD","BK4585","LU1804176565.USD","BK4007","IE00B1BXHZ80.USD","LU0122379950.USD","LU1712237335.SGD","LU0096364046.USD","IE00BJJMRZ35.SGD","BK4534","LU0943347566.SGD","IE0009355771.USD","LU1551013342.USD","LU1623119135.USD","LU0256863811.USD","LU1035775433.USD","LU0109391861.USD","LU0079474960.USD","IE0004445239.USD","LU0882574055.USD","IE00BFTCPJ56.SGD","IE00BJLML261.HKD","LU0289739699.SGD","LU0823416689.USD","BK4533","LU1061106388.HKD","LU0114720955.EUR","LU1551013425.SGD","BK4516","LU0058720904.USD","LU1280957306.USD","LU0061475181.USD","LU0466842654.USD","LU0385154629.USD","LU0882574139.USD","GLP","IE0002141913.USD","LU0820561909.HKD","LU0689472784.USD","LU0471298694.HKD","LU1057294990.SGD","LU1064131342.USD","LU0094547139.USD"],"gpt_icon":1},{"id":"2452441340","title":"礼来公司的减肥药替西帕肽在中国获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452441340","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2452441340?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:40","pubTimestamp":1721378400,"startTime":"0","endTime":"0","summary":"诺和诺德的减肥药Wegovy于6月份获得了中国的批准，中国是世界第二大经济体，估计也是超重或肥胖人数最多的国家，此举使其股价飙升 。礼来公司的发言人没有立即回应关于该公司的药品何时开始在中国销售或将供应多少剂量的置评请求。美国礼来公司的糖尿病药物蒙加罗和减肥药物Zepbound的活性成分都是替齐帕特，蒙加罗也已在中国获批 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0672654240.SGD","LU1804176565.USD","LU1551013342.USD","IE00BFTCPJ56.SGD","LU0882574139.USD","LU1712237335.SGD","BK4533","LU0114720955.EUR","LU0385154629.USD","LU0689472784.USD","LU0097036916.USD","LU1061106388.HKD","IE00BK4W5M84.HKD","IE0004445239.USD","LU0943347566.SGD","IE0009355771.USD","BK4588","BK4534","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0058720904.USD","LU0079474960.USD","LU0289739699.SGD","LU1035775433.USD","LU1057294990.SGD","LU0096364046.USD","LU1069344957.HKD","LU1551013425.SGD","LU1280957306.USD","LU1023059063.AUD","LU0094547139.USD","LU0820561818.USD","GB00BDT5M118.USD","LU0882574055.USD","LLY","LU0466842654.USD","IE0002141913.USD","BK4581","IE00BJLML261.HKD","LU0109391861.USD","LU0122379950.USD","LU0708995401.HKD","LU0820561909.HKD","BK4007","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU1623119135.USD","LU0061475181.USD","LU0256863811.USD","NVO","LU0471298694.HKD"],"gpt_icon":1},{"id":"1110119848","title":"诺和诺德、礼来均跌超5%！“减肥药双雄”连续两个交易日大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1110119848","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1110119848?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:12","pubTimestamp":1721315557,"startTime":"0","endTime":"0","summary":"7月18日，$诺和诺德(NVO)$、$礼来(LLY)$均跌超5%，“减肥药双雄”连续两个交易日大跌。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0466842654.USD","LU0471298694.HKD","LLY","LU0122379950.USD","LU1551013425.SGD","LU0096364046.USD","LU0882574055.USD","BK4532","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","LU1035775433.USD","BK4585","LU0689472784.USD","LU1064131342.USD","NVO","IE00BK4W5M84.HKD","LU1061106388.HKD","NVO.AU","IE00BKVL7J92.USD","LU0097036916.USD"],"gpt_icon":0},{"id":"2452433561","title":"诺和诺德盘中异动 早盘股价大跌5.03%报128.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452433561","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452433561?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:04","pubTimestamp":1721315063,"startTime":"0","endTime":"0","summary":"北京时间2024年07月18日23时04分，诺和诺德股票出现异动，股价急速跳水5.03%。截至发稿，该股报128.61美元/股，成交量331.777万股，换手率0.07%，振幅4.73%。诺和诺德股票所在的生物技术行业中，整体跌幅为1.51%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。目前，在全球范围内，唯一获批的口服GLP-1制剂就是诺和诺德旗下的司美格鲁肽片剂Rybelsus。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718230424aefa5998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718230424aefa5998&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4585","LU0154236417.USD","NVO","BK4007","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4588"],"gpt_icon":1},{"id":"2452119261","title":"行业巨震！罗氏新药 “吓坏”减肥药板块 礼来与诺和诺德应声下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2452119261","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452119261?lang=zh_cn&edition=full","pubTime":"2024-07-18 08:00","pubTimestamp":1721260800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在瑞士制药巨头罗氏宣布其口服减肥药临床试验取得积极结果后，礼来与诺和诺德股价周三下跌。罗氏周三表示，收购Carmot Therapeutics获得的第二种候选药物显示出积极的效果，这进一步加剧了减肥药市场的竞争。截至周三美股收盘，罗氏上涨7.53%，Wegovy生产商诺和诺德下跌3.87%，Zepbound生产商礼来下跌3.82%，减肥药新贵Viking Therapeutics下跌12.56%。今年1月，罗氏完成了对减肥药开发商Carmot Therapeutics的收购。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152376.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0640476718.USD","LU0689472784.USD","LU0456855351.SGD","LU0823416689.USD","IE0002141913.USD","LU0820561818.USD","BK4588","LU1069344957.HKD","LU0154236417.USD","LU1551013342.USD","LU1804176565.USD","LU0097036916.USD","LU0320765059.SGD","LU1623119135.USD","LU0256863902.USD","GB00BDT5M118.USD","LU0820561909.HKD","LU1064131342.USD","BK4581","LU1061106388.HKD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","IE00BKVL7J92.USD","LLY","LU0385154629.USD","IE00BZ1G4Q59.USD","LU0238689110.USD","LU0471298777.SGD","LU0882574139.USD","LU1712237335.SGD","NVO","LU0079474960.USD","LU0289739699.SGD","LU0943347566.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4516","LU0096364046.USD","IE0009355771.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0256863811.USD","LU0417517546.SGD","LU0466842654.USD","LU0198837287.USD","LU1267930730.SGD","BK4585","LU0672654240.SGD"],"gpt_icon":1},{"id":"2452071163","title":"背景资料-减肥药开发商排队开发价值 1500 亿美元的市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2452071163","media":"Reuters","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452071163?lang=zh_cn&edition=full","pubTime":"2024-07-17 22:51","pubTimestamp":1721227909,"startTime":"0","endTime":"0","summary":"Wegovy与诺和诺德的糖尿病药物Ozempic使用相同的活性成分，于2021年获得批准。该公司报告说，在12月Zepbound上市的头几周， ，销售额达1.758亿美元。根据这项研究的数据，经过13周的治疗，VK2735帮助患者实现了高达14.7%的平均体重减轻。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","LU1623119135.USD","LU1894683348.USD","LU1069344957.HKD","NVO","LU0256863811.USD","IE00BKVL7J92.USD","ALT","GPCR","LU0096364046.USD","BK4532","BK4592","IE00BJJMRZ35.SGD","LU0820561818.USD","LU0466842654.USD","LU1551013425.SGD","LU1894683264.USD","SG9999001176.SGD","LU0321505868.SGD","LU0471298694.HKD","SG9999003800.SGD","LU0385154629.USD","LU0097036916.USD","LU1066051498.USD","IE0002141913.USD","BK4588","BK4581","LU1804176565.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1712237335.SGD","LU2112291526.USD","LU0943347566.SGD","LU1878469433.USD","IE00BJLML261.HKD","OPK","LU1061106388.HKD","PFE","LU2242652126.USD","GB00BDT5M118.USD","IE0009355771.USD","LU0114720955.EUR","SG9999011175.SGD","LU0079474960.USD","AMGN","LU0882574055.USD","LU0882574139.USD","LLY","IE0004445239.USD","LU0109394709.USD"],"gpt_icon":1},{"id":"1167017119","title":"罗氏口服减肥药临床试验取得积极结果！减肥药概念股闻讯下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1167017119","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1167017119?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:41","pubTimestamp":1721223718,"startTime":"0","endTime":"0","summary":"7月17日，罗氏控股涨近8%，公司称其口服减肥药临床试验取得积极结果；受此消息影响，$诺和诺德(NVO)$、$礼来(LLY)$、Viking减肥药概念股集体下挫。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1804176565.USD","LU0471298694.HKD","BK4585","RHHBY","VKTX","LU0689472784.USD","LU0097036916.USD","IE00BK4W5M84.HKD","BK4534","LU0096364046.USD","LU0882574055.USD","BK4532","LLY","LU0466842654.USD","IE00BJLML261.HKD","LU0122379950.USD","LU0820561909.HKD","IE00B1BXHZ80.USD","IE00BK4W5L77.USD","NVO","LU1061106388.HKD"],"gpt_icon":0},{"id":"2452151905","title":"“诺礼”惊出一身冷汗！罗氏口服减肥药临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2452151905","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452151905?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:20","pubTimestamp":1721222413,"startTime":"0","endTime":"0","summary":"罗氏旗下Genentech表示，其口服GLP-1受体激动剂CT-996在1期临床试验中的四周内平均体重减轻了约6%。","market":"sg","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152309.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“诺礼”惊出一身冷汗！罗氏口服减肥药临床试验取得积极结果","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VKTX","BK4007","NVO","BK1141","BK1583","LLY","BK1576"],"gpt_icon":0},{"id":"2452592411","title":"劲敌来了！罗氏口服减肥药早期试验结果乐观，诺和诺德和礼来股价齐跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2452592411","media":"华尔街见闻","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452592411?lang=zh_cn&edition=full","pubTime":"2024-07-17 20:57","pubTimestamp":1721221043,"startTime":"0","endTime":"0","summary":"罗氏称，其实验性口服减肥药CT-996在一项I期试验中，能够使患II型糖尿病的肥胖症患者的平均体重在四周内减少6.1%。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/e956a03b-5d62-434b-8743-3d6009dcd314.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/e956a03b-5d62-434b-8743-3d6009dcd314.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3719915","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3719915","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0096364046.USD","LU1712237335.SGD","IE00BFTCPJ56.SGD","BK4516","LU0097036916.USD","LU1023059063.AUD","BK4532","LU0094547139.USD","LU0109391861.USD","LU0689472784.USD","LU0820561909.HKD","BK4534","MRNA","LU1069344957.HKD","IE0009355771.USD","LU0456855351.SGD","IE00BK4W5M84.HKD","LU0238689110.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU0114720955.EUR","LU0154236417.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0256863902.USD","LU1623119135.USD","NVO","LU0823416689.USD","LU0708995401.HKD","LU0320765059.SGD","IE00BK4W5L77.USD","IE00B4R5TH58.HKD","LU0471298777.SGD","LU0672654240.SGD","LU0466842654.USD","LU0198837287.USD","BK4007","LU0385154629.USD","LU0417517546.SGD","BK4585","LU0061475181.USD","LU0882574139.USD","LU1267930730.SGD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU1064131342.USD","LU0640476718.USD","IE00BJT1NW94.SGD","LU0820561818.USD","BK4533"],"gpt_icon":1},{"id":"1129361092","title":"多重利空消息突袭！减肥药双雄盘前集体走低","url":"https://stock-news.laohu8.com/highlight/detail?id=1129361092","media":"老虎资讯综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1129361092?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:37","pubTimestamp":1721209054,"startTime":"0","endTime":"0","summary":"7月17日，$诺和诺德(NVO)$美股盘前跌超3%，消息面上，由于费用高昂且对于长期使用存在不确定因素，荷兰不愿意将诺和诺德的减重药物Wegovy纳入其基本医疗保险计划。政府机构于周二告知医疗保健部长Fleur Agema，Wegovy的费用报销可能达到每年1.3亿欧元，且不确定这种昂贵的药物是否需要终身使用。诺和诺德表示，该机构的建议让人失望，希望按照治疗指南的要求，仅针对一小部分控制范围内的群体提供Wegovy费用报销。目前，荷兰约有400万符合使用Wegovy的人。此外，知情人士表示，美国参议院民主党幕僚将与诺和诺德高管会面，讨论该公司停止在美国销售一种长效胰岛素的决定所带来的影响。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"多重利空消息突袭！减肥药双雄集体走低","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4007","BK4588","LU0154236417.USD","BK4585","IE00BKVL7J92.USD","LLY","IE00BZ1G4Q59.USD","BK4532"],"gpt_icon":0},{"id":"2452019133","title":"诺和诺德(NVO)盘前跌超3% 荷兰医疗保健对报销Novo Nordisk的肥胖治疗药物费用持谨慎态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2452019133","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452019133?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:21","pubTimestamp":1721208073,"startTime":"0","endTime":"0","summary":"金吾财讯 | 截至发稿，诺和诺德(NVO)盘前跌超3%，报136美元。消息面上，荷兰医疗保健对报销Novo Nordisk的肥胖治疗药物费用持谨慎态度。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277870","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","LU0154236417.USD","BK4007"],"gpt_icon":1},{"id":"2451509949","title":"传诺和诺德因停止长效胰岛素Levemir在美销售而面临美国国会审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2451509949","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2451509949?lang=zh_cn&edition=full","pubTime":"2024-07-16 16:50","pubTimestamp":1721119800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，两位知情人士表示，美国参议院民主党幕僚周二将与诺和诺德高管会面，讨论该公司停止在美国销售一种长效胰岛素的决定所带来的影响。沙欣的办公室证实了与诺和诺德的会面计划，但拒绝提供细节。去年11月，诺和诺德宣布在美国停止Levemir的销售，理由是生产限制、患者获取途径减少以及现有替代品——包括另一种长效胰岛素Tresiba。诺和诺德的另一种长效胰岛素Tresiba去年的销售额为13.3亿克朗。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151478.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺和诺德因停止Levemir在美销售面临审查","news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","IE00BKVL7J92.USD","BK4585","IE00BZ1G4Q59.USD","BK4532","NVO","LU0154236417.USD"],"gpt_icon":0},{"id":"2451955251","title":"诺和诺德支持瑞士生物技术公司 Asceneuron 完成 1 亿美元融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2451955251","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451955251?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:00","pubTimestamp":1721113208,"startTime":"0","endTime":"0","summary":" Maggie Fick    路透伦敦7月16日 - 瑞士生物技术公司Asceneuron周二表示，它已从包括Wegovy生产商诺和诺德公司控股股东在内的投资者那里筹集到1亿美元，用于资助其阿尔茨海默病药物的临床开发。Asceneuron公司的领先实验药物ASN51属于一类新药，被称为O-GlcNA酶 抑制剂。一周前，诺和诺德控股公司牵头为英国生物技术公司Myricx Pharma单独进行了一轮9000万英镑，以推进其实验性癌症药物的研发。诺和诺德控股公司的投资资金也在不断增加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","LU0208291251.USD","LU0154236417.USD","LU0672654240.SGD","LU0965509101.SGD","LU0070302665.USD","IE00B19Z9Z06.USD","LU0266013472.USD","IE00B894F039.SGD","IE00BZ1G4Q59.USD","LU1267930730.SGD","LU0965509010.AUD","LU1037948897.HKD","LU1585245621.USD","LU1974910355.USD","IE00BK4W5L77.USD","IE00BLSP4239.USD","LU0965508806.USD","MRK","BK4588","LU1430594728.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","IE00B4R5TH58.HKD","LU0238689110.USD","IE00BLSP4452.SGD","NVO","LU0456855351.SGD","LU1941712348.USD","BIIB","LU0320765059.SGD","LU0471298777.SGD","LU1037948541.HKD","LU0417517546.SGD","LU1941712264.USD","LU1023059063.AUD","LU0289739699.SGD","LU1934455277.USD","LU0234572021.USD","LU1934455194.USD","BK4581","LU0234570918.USD","LU0265550946.USD","IE00BSNM7G36.USD","IE00B2B36J28.USD","LLY","LU0256863902.USD","LU1291159041.SGD","IE00BK4W5M84.HKD","BK4139"],"gpt_icon":0},{"id":"2450802185","title":"欧盟指控礼来(LLY.US)与诺和诺德(NVO.US)减肥药和降糖药存在麻醉后肺吸入风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2450802185","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450802185?lang=zh_cn&edition=full","pubTime":"2024-07-12 20:56","pubTimestamp":1720788976,"startTime":"0","endTime":"0","summary":"智通财经获悉，欧洲卫生部门表示，如果即将接受手术的患者正在服用诺和诺德和礼来的降糖药和减肥药，应注意有出现麻醉并发症的风险。欧洲药品管理局安全委员会建议接受GLP-1药物治疗的患者在接受全身麻醉或深度镇静手术前告知医生，并表示产品信息将相应更新。欧盟去年要求包括诺和来和礼来在内的四家公司提供更多关于可能出现的麻醉并发症的信息，随后发布了最新指导意见。胃里的液体进入肺部会使病人有患肺炎的危险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0094547139.USD","LU0882574055.USD","LU0471298777.SGD","IE00B4R5TH58.HKD","LU0820561909.HKD","LU0122379950.USD","LU0320765059.SGD","BK4534","LU1267930730.SGD","BK4532","LU0471298694.HKD","LU1804176565.USD","LU1035775433.USD","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","IE0004445239.USD","LU0109391861.USD","IE00B2B36J28.USD","LU0823416689.USD","LU1280957306.USD","LU0154236417.USD","LU0417517546.SGD","LU0289739699.SGD","LU1551013342.USD","IE00BJJMRZ35.SGD","LU0943347566.SGD","LU0689472784.USD","BK4533","LU1057294990.SGD","LU1061106388.HKD","LU0456855351.SGD","IE00BJLML261.HKD","LU0061475181.USD","NVO","LU0256863902.USD","LU0198837287.USD","LU0882574139.USD","LU0385154629.USD","LU0079474960.USD","LU0640476718.USD","LU0820561818.USD","LU0096364046.USD","LU1064131342.USD","LU1623119135.USD","LU0097036916.USD","LLY","LU0708995401.HKD","BK4007"],"gpt_icon":0},{"id":"2450107301","title":"牛津大学研究显示：诺和诺德(NVO.US)减肥药Ozempic与降低痴呆发病率有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2450107301","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450107301?lang=zh_cn&edition=full","pubTime":"2024-07-12 17:30","pubTimestamp":1720776647,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，牛津大学的一项研究表明，诺和诺德旗下减肥药物Ozempic与降低痴呆和一系列其他精神疾病的发病率有关，这提高了人们对这种减肥药物潜在益处的期望。此外，研究还表明，与服用格列吡嗪的患者相比，服用Ozempic的患者的吸烟风险降低了28%。利物浦大学医学教授John Wilding表示，这意味着需要更多的研究来“确定Semagelutide是否确实对减少糖尿病患者的认知功能障碍或影响吸烟率有好处”。Semagelutide是诺和诺德旗下减肥药物Ozempic和Wegovy的主要成分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4007","IE00BKVL7J92.USD","BK4588","LU0154236417.USD","BK4585","BK4532","IE00BZ1G4Q59.USD","NVO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0742},{"period":"1month","weight":-0.0658},{"period":"3month","weight":0.072},{"period":"6month","weight":0.2298},{"period":"1year","weight":0.5995},{"period":"ytd","weight":0.2715}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005324},{"month":8,"riseRate":0.511628,"avgChangeRate":0.000647},{"month":9,"riseRate":0.581395,"avgChangeRate":0.000639},{"month":10,"riseRate":0.511628,"avgChangeRate":-0.000902},{"month":11,"riseRate":0.627907,"avgChangeRate":0.028932},{"month":12,"riseRate":0.744186,"avgChangeRate":0.054828}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}